Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation.
about
Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsisTissue factor pathway inhibitor and thrombin activatable fibrinolytic inhibitor plasma levels following burn and septic injuries in ratsClinical significance of expression of tissue factor and tissue factor pathway inhibitor in ulcerative colitisCritical care medicine in AJRCCM 2000.Pharmacotherapy of acute respiratory distress syndrome.Inflammation and thrombosis.Interleukin 6 mediates the therapeutic effects of adipose-derived stromal/stem cells in lipopolysaccharide-induced acute lung injuryFeasibility and Safety of Local Treatment with Recombinant Human Tissue Factor Pathway Inhibitor in a Rat Model of Streptococcus pneumoniae Pneumonia.Tissue factor and tissue factor pathway inhibitor.Myeloid tissue factor does not modulate lung inflammation or permeability during experimental acute lung injury.Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndromeA clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumoniaTissue factor as an initiator of coagulation and inflammation in the lung.Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition.Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity.A review of pulmonary coagulopathy in acute lung injury, acute respiratory distress syndrome and pneumonia.Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndromeMicroparticles and acute lung injury.Impact of thrombosis on pulmonary endothelial injury and repair following sepsis.Mechanisms of attenuation of abdominal sepsis induced acute lung injury by ascorbic acid.Raised protein levels and altered cellular expression of factor VII activating protease (FSAP) in the lungs of patients with acute respiratory distress syndrome (ARDS).Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial.Anticoagulant therapy in acute respiratory distress syndrome.Endogenous tissue factor pathway inhibitor has a limited effect on host defence in murine pneumococcal pneumonia.
P2860
Q24794692-FF2F71CB-6A88-4596-AAA3-F5400C074CDFQ28573067-818A8BD6-324D-4CB9-B8DB-1B60D6AA15DBQ33780202-3AFC7E6B-743C-4F15-A4A7-0714B606E04AQ34435267-5580CEBD-AA96-4CB3-84FF-BE94A331D2F4Q34706893-06695046-145E-4604-B603-56BEB60C3695Q35181574-A1FD8DB1-5141-4E54-A94A-20E99874069AQ35195085-830FCB35-0BBD-48BA-870B-63FA63585FC4Q35636201-9ED1B136-3DF5-4484-A015-2618DAEABA82Q35750758-ECA54354-E2A7-466A-B9F4-E9BB585777AEQ36628191-21DF27BC-1186-4118-BE3C-E8B93E0E9AF4Q36835719-D5B8FF62-AC4E-4349-A0AB-73000878BE46Q37210059-E491FB82-DF59-43CC-AEDC-8465A2927930Q37357364-9A77778D-A798-430C-B99A-5FBC072D34FDQ37357367-6C2D09AE-7CBE-4C3F-AE51-1DAC9A98DBC1Q37393718-23ADE3BD-3D77-45E6-A5B3-0E212350E9C1Q37394274-936082DF-E76B-49A4-81E8-27150BCA7C65Q37852747-5CE8229C-532A-4817-A2A2-373BB8F238BEQ38021265-C535B4A7-F1D4-41F8-869E-9ED22380BC11Q39107051-F962A89F-3C04-4D29-9683-284D5038EC79Q39361006-6F43997E-5BF1-474D-85B9-50C161B3364CQ40644467-BA6B431F-FC4B-4D2E-95A2-16931F672F03Q43903326-E93F2C63-0030-4A8A-B592-96F15366B36AQ50072766-15BCD566-B6F0-45C5-BB07-CFCACB9D87C6Q55123953-944CB5D2-8FBC-42D8-91D1-DC4FF1FCED67
P2860
Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Recombinant tissue factor path ...... hibiting leukocyte activation.
@ast
Recombinant tissue factor path ...... hibiting leukocyte activation.
@en
type
label
Recombinant tissue factor path ...... hibiting leukocyte activation.
@ast
Recombinant tissue factor path ...... hibiting leukocyte activation.
@en
prefLabel
Recombinant tissue factor path ...... hibiting leukocyte activation.
@ast
Recombinant tissue factor path ...... hibiting leukocyte activation.
@en
P2093
P2860
P1476
Recombinant tissue factor path ...... hibiting leukocyte activation.
@en
P2093
Enkhbaatar P
Murakami K
Yamaguchi Y
P2860
P304
P356
10.1164/AJRCCM.162.5.9911018
P407
P577
2000-11-01T00:00:00Z